Celiac Disease Treatment Market Research Report - Global Forecast till 2027

Global Celiac Disease Treatment Market Research Report: By Treatment, By End-User (Hospitals and clinics, Clinical Research Organizations, Research & Academic Institutes) – Forecast to 2027

ID: MRFR/HC/7002-HCR | February, 2021 | Region : Global

Market Forecast


Celiac Disease Treatment Market is estimated to grow at a CAGR of 18.60% during the forecast period, 2019-2025, and reach USD 661.2 Million by 2025.


Market Synopsis


Increasing prevalence of diabetes and celiac disease is expected to drive the global market.


The rising pediatric population is likely to boost the celiac disease treatment market. Traditionally, celiac disease is considered a pediatric disorder. Typically, the disorders occur after the introduction of weaning foods containing prolamines in children, 6 to 18 months old. Thus, growing pediatric population is estimated to drive market growth.


Market Influencer


Rising clinical trials of drugs against celiac disease is estimated to influence the celiac disease treatment market. The market is projected to witness a shift from symptomatic to targeted treatments, during the forecast period, 2018-2025.


Market Drivers



  • Increasing diabetes cases.


Celiac disease is a chronic inflammatory disorder of the small intestine, caused by the ingestion of dietary gluten products. The disease is multifactorial, and various triggering factors (environmental factors and genetic makeup of the patients) is responsible for primary symptoms.


It is reported that type-1 diabetes is one of the most widely studied disorders associated with celiac disease. It has been established that the prevalence of celiac disease ranges from 1%-19% amongst type 1 diabetes mellitus patients.



  • Favorable government policies across the Western world

  • Increasing number of clinical trials for drugs against celiac disease

  • Rising awareness for the diseases

  • Increasing penetration of therapeutic products in the developing economies


Market Restraints



  • Limited availability of the treatment options available in the market



  • A majority of the treatment options available in the market for celiac disease rely on a gluten-free diet, including gluten-free bakery products, gluten-free baby food, and others. There is no specific drug for the treatment of the disease.



  • Underdiagnosis/misdiagnosis of celiac disease



  • A majority of the celiac disease cases remain underdiagnosed/misdiagnosed, restricting market growth. It is estimated that approximately 83% of the Americans who have celiac disease are undiagnosed or misdiagnosed with other conditions.


Segmentation


By Treatment



  • Gluten-Free Diet segment held the largest market share in the market in 2018. A majority of the patients who have celiac disease rely on gluten-free (in the absence of targeted drugs).



  • Vitamin & mineral supplements and enzyme supplement therapy led the market after a gluten-free diet. The market by this segment is estimated to show positive growth during the forecast period.



  • The medications segment held the least market share in 2018. The segment’s market value is projected to grow during the forecast period, owing to a developing drug pipeline against the celiac disease.


By End-User



  • Hospitals and clinics: By end-user, hospitals and clinics hold the largest market share. Favorable government policies and rising awareness campaigns across the globe are responsible for increasing the number of patients seeking treatment through primary healthcare facilities, i.e., hospitals and clinics.



  • Clinical Research Organizations: A growing segment owing to an increasing number of clinical trials.



  • Research & Academic Institutes: Technology advances and research and development collaborations are leading to market growth by this segment.


By Region



  • Americas: Americas is the largest regional market for celiac treatment. Increasing prevalence of celiac disease and the presence of major market players such as Innovate Biopharmaceuticals Inc. drives the market within the region. The prevalence of celiac disease is estimated to be as high as 4.0% within South Africa.



  • Europe: Followed by the Americas, Europe stood second in the global celiac disease treatment market (in 2018). Rising healthcare expenditure and the presence of developed economies drive the European celiac disease treatment market. In 2016, ~USD 5,490.1 was the per capita healthcare expenditure within Europe.



  • Asia-Pacific: Asia-Pacific is estimated to be the fastest-growing regional market for celiac disease treatment. Asia-Pacific has the world’s largest population and fast-developing healthcare industry.



  • Middle East & Africa: Underdeveloped infrastructural chain of the region makes it very difficult for the manufactures to reach their consumers. Moreover, the presence of stringent government regulations restraints market growth.


Key Players



  • Amgen Inc. (US)

  • Amneal Pharmaceuticals LLC (US)

  • BioLineRx (Israel)

  • Calypso Biotech SA (Switzerland)

  • Freedom Foods Group Limited (Australia)

  • General Mills, Inc. (US)

  • Glenmark Pharmaceuticals Inc. (India)

  • Hain Celestial Group, Inc. (US)

  • Innovate Biopharmaceuticals Inc. (US)

  • Kellogg Company (US)

  • Mondelez International Inc. (US)

  • Mylan Pharmaceuticals Inc. (US)

  • Pinnacle Foods, Inc. (US)

  • Selecta Biosciences, Inc (US)

  • Takeda Pharmaceutical Company Ltd (Japan)

  • The Kraft Heinz Company (US)

  • West-Ward Pharmaceutical (US)

  • Zedira GmbH (Germany)

  • Zydus Pharmaceuticals Inc. (US)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis


6. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY TREATMENT

6.1. Overview

6.2. Gluten-Free Diet

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.1 Gluten-Free Bakery Products

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Gluten-Free Baby Food

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3 Gluten-Free Pasta

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.4 Gluten-Free Meals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Vitamin and Mineral Supplements

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Medications

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.1 Azathioprine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.2 Budesonide

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027


7. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY END USER

7.1. Overview

7.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Clinical Research Organizations

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1.1. Overview

9.1.2. Competitive Analysis

10. COMPANY PROFILES

10.1. Amgen Inc. (US)

10.1.1. Company Overview

10.1.2. Type Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Amneal Pharmaceuticals LLC (US)

10.2.1. Company Overview

10.2.2. Type Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. BioLineRx (Israel)

10.3.1. Company Overview

10.3.2. Type Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Calypso Biotech SA (Switzerland)

10.4.1. Company Overview

10.4.2. Type Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Freedom Foods Group Limited (Australia)

10.5.1. Company Overview

10.5.2. Type Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. General Mills, Inc. (US)

10.6.1. Company Overview

10.6.2. Type Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Glenmark Pharmaceuticals Inc. (India)

10.7.1. Company Overview

10.7.2. Type Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Hain Celestial Group, Inc. (US)

10.8.1. Company Overview

10.8.2. Type Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Innovate Biopharmaceuticals Inc. (US)

10.9.1. Company Overview

10.9.2. Type Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Kellogg Company (US)

10.10.1. Company Overview

10.10.2. Type Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Mondelez International Inc. (US)

10.11.1. Company Overview

10.11.2. Type Overview

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Mylan Pharmaceuticals Inc. (US)

10.12.1. Company Overview

10.12.2. Type Overview

10.12.3. Financial Overview

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies


10.13. Pinnacle Foods, Inc. (US)

10.13.1. Company Overview

10.13.2. Type Overview

10.13.3. Financial Overview

10.13.4. Key Developments

10.13.5. SWOT Analysis

10.13.6. Key Strategies

10.14. Selecta Biosciences, Inc (US)

10.14.1. Company Overview

10.14.2. Type Overview

10.14.3. Financial Overview

10.14.4. Key Developments

10.14.5. SWOT Analysis

10.14.6. Key Strategies

10.15. Takeda Pharmaceutical Company Ltd (Japan)

10.15.1. Company Overview

10.15.2. Type Overview

10.15.3. Financial Overview

10.15.4. Key Developments

10.15.5. SWOT Analysis

10.15.6. Key Strategies

10.16. The Kraft Heinz Company (US)

10.16.1. Company Overview

10.16.2. Type Overview

10.16.3. Financial Overview

10.16.4. Key Developments

10.16.5. SWOT Analysis

10.16.6. Key Strategies

10.17. West-Ward Pharmaceutical (US)

10.17.1. Company Overview

10.17.2. Type Overview

10.17.3. Financial Overview

10.17.4. Key Developments

10.17.5. SWOT Analysis

10.17.6. Key Strategies

10.18. Zedira GmbH (Germany)

10.18.1. Company Overview

10.18.2. Type Overview

10.18.3. Financial Overview

10.18.4. Key Developments

10.18.5. SWOT Analysis

10.18.6. Key Strategies

10.19. Zydus Pharmaceuticals Inc. (US)

10.19.1. Company Overview

10.19.2. Type Overview

10.19.3. Financial Overview

10.19.4. Key Developments

10.19.5. SWOT Analysis

10.19.6. Key Strategies

10.20. Others

11. APPENDIX

11.1. References

11.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL CELIAC DISEASE TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL CELIAC DISEASE TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 6 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 US: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 US: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 CANADA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 11 CANADA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 LATIN AMERICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 13 LATIN AMERICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 17 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 18 EASTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 19 EASTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELIAC DISEASE TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELIAC DISEASE TREATMENT MARKET

FIGURE 4 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 5 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 6 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7AMERICAS: CELIAC DISEASE TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 8 EUROPE: CELIAC DISEASE TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 GLOBAL CELIAC DISEASE TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 AMGEN INC.: KEY FINANCIALS

FIGURE 14 AMGEN INC.: SEGMENTAL REVENUE

FIGURE 15 AMGEN INC.: REGIONAL REVENUE

FIGURE 16 AMNEAL PHARMACEUTICALS LLC: KEY FINANCIALS

FIGURE 17 AMNEAL PHARMACEUTICALS LLC: SEGMENTAL REVENUE

FIGURE 18 AMNEAL PHARMACEUTICALS LLC: REGIONAL REVENUE

FIGURE 19 BIOLINERX: KEY FINANCIALS

FIGURE 20 BIOLINERX: SEGMENTAL REVENUE

FIGURE 21 BIOLINERX: REGIONAL REVENUE

FIGURE 22 CALYPSO BIOTECH SA: KEY FINANCIALS

FIGURE 23 CALYPSO BIOTECH SA: SEGMENTAL REVENUE

FIGURE 24 CALYPSO BIOTECH SA: REGIONAL REVENUE

FIGURE 25 FREEDOM FOODS GROUP LIMITED: KEY FINANCIALS

FIGURE 26 FREEDOM FOODS GROUP LIMITED: SEGMENTAL REVENUE

FIGURE 27 FREEDOM FOODS GROUP LIMITED: REGIONAL REVENUE

FIGURE 28 GENERAL MILLS, INC.: KEY FINANCIALS

FIGURE 29 GENERAL MILLS, INC.: SEGMENTAL REVENUE

FIGURE 30 GENERAL MILLS, INC.: REGIONAL REVENUE

FIGURE 31 GLENMARK PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 32 GLENMARK PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 33 GLENMARK PHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 34 HAIN CELESTIAL GROUP, INC.: KEY FINANCIALS

FIGURE 35 HAIN CELESTIAL GROUP, INC.: SEGMENTAL REVENUE

FIGURE 36 HAIN CELESTIAL GROUP, INC.: REGIONAL REVENUE

FIGURE 37 INNOVATE BIOPHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 38 INNOVATE BIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 39 INNOVATE BIOPHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 40 KELLOGG COMPANY: KEY FINANCIALS

FIGURE 41 KELLOGG COMPANY: SEGMENTAL REVENUE

FIGURE 42 KELLOGG COMPANY: REGIONAL REVENUE

FIGURE 43 MONDELEZ INTERNATIONAL INC.: KEY FINANCIALS

FIGURE 44 MONDELEZ INTERNATIONAL INC.: SEGMENTAL REVENUE

FIGURE 45 MONDELEZ INTERNATIONAL INC.: REGIONAL REVENUE

FIGURE 46 MYLAN PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 47 MYLAN PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 48 MYLAN PHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 49 PINNACLE FOODS, INC.: KEY FINANCIALS

FIGURE 50 PINNACLE FOODS, INC.: SEGMENTAL REVENUE

FIGURE 51 PINNACLE FOODS, INC.: REGIONAL REVENUE

FIGURE 52 SELECTA BIOSCIENCES, INC: KEY FINANCIALS

FIGURE 53 SELECTA BIOSCIENCES, INC: SEGMENTAL REVENUE

FIGURE 54 SELECTA BIOSCIENCES, INC: REGIONAL REVENUE

FIGURE 55 TAKEDA PHARMACEUTICAL COMPANY LTD: KEY FINANCIALS

FIGURE 56 TAKEDA PHARMACEUTICAL COMPANY LTD: SEGMENTAL REVENUE

FIGURE 57 TAKEDA PHARMACEUTICAL COMPANY LTD: REGIONAL REVENUE

FIGURE 58 THE KRAFT HEINZ COMPANY: KEY FINANCIALS

FIGURE 59 THE KRAFT HEINZ COMPANY: SEGMENTAL REVENUE

FIGURE 60 THE KRAFT HEINZ COMPANY: REGIONAL REVENUE

FIGURE 61 WEST-WARD PHARMACEUTICAL: KEY FINANCIALS

FIGURE 62 WEST-WARD PHARMACEUTICAL: SEGMENTAL REVENUE

FIGURE 63 WEST-WARD PHARMACEUTICAL: REGIONAL REVENUE

FIGURE 64 ZEDIRA GMBH: KEY FINANCIALS

FIGURE 65 ZEDIRA GMBH: SEGMENTAL REVENUE

FIGURE 66 ZEDIRA GMBH: REGIONAL REVENUE

FIGURE 67 ZYDUS PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 68 ZYDUS PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 69 ZYDUS PHARMACEUTICALS INC.: REGIONAL REVENUE




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.